We studied human placental microvillous EGF receptor (EGFR) and its relationship with maternal and placental features in 14 cases of intrauterine growth retardation.
Introduction
EGF is a multifunctional 53-amino acid peptide factor first known for its mitogenic action on epidermal and mesodermal cells ( 1 ) . Several lines of evidence point to a prominent role of EGF in human placental growth and function. In humans, EGF is involved in embryonal implantation (2) , stimulates syncytiotrophoblast differentiation in vitro (3) , and modulates placental endocrine functions (3) (4) (5) (6) .
The effects of EGF on target cells are mediated by the EGF receptor (EGFR),' a transmembrane glycoprotein of 170 kD. Binding of EGF stimulates the receptor intracellular tyrosine kinase domain, which induces the phosphorylation of three tyrosine residues located on the COOH-terminal region. This autophosphorylation process is required for the transmission of the EGF message to the cell and the control of cell division and differentiation (reviewed in reference 7) .
EGFR is strongly expressed in the human placenta and its expression is modulated in various physiological conditions. An increase in EGF receptor numbers occurs during placental ontogenesis (8) (9) (10) , syncytiotrophoblast formation in vitro ( 11 ) , and after treatment of trophoblast cells with polypeptide hormones such as PTH (12) .
Throughout gestation, EGFR is expressed predominantly on the apical microvillous plasma membrane of the syncytiotrophoblast ( 1 3, 14) , which is a multifunctional tissue in contact with the maternal blood; the syncytiotrophoblast supports materno-fetal exchanges and secretes peptide and steroid hormones ( 15, 16) .
Interestingly, alterations of human placental EGFR have been described in pathological and high risk pregnancies; these include decreased tyrosine kinase activity in smokers ( 17) and a loss ofEGF binding sites in cases ofintrauterine growth retardation (IUGR) ( 18 ) . Few studies have been done in the latter setting.
Intrauterine growth retardation occurs in 3-5% ofpregnancies ( 19) and is a major risk factor for perinatal mortality and morbidity (20) (21) (22) . Neonates with IUGR are highly heterogeneous: fetal chromosome disorders, maternal hypertension, drug addiction, and smoking are considered as strong risk factors for IUGR (23) (24) , but the possible relationship between maternal factors, IUGR, placental abnormalities, and EGFR alterations has not been examined.
To characterize EGFR in IUGR placentas and to improve our understanding ofIUGR, we undertook a prospective study of 14 third trimester placentas corresponding to small for gestational age (SGA) neonates, analyzing clinical maternal and neonatal features, the histopathological aspect ofthe placentas, and the biochemical nature of placental EGFR.
Methods
Recruitment. Pregnant women were recruited at the H6pital Robert Debre (Paris, France) when they came for delivery or antenatal testing.
1. Abbreviations used in this paper: AGA, appropriate for gestational age; B,, maximal binding capacity; EGFR, epidermal growth factor receptor; IUGR, intrauterine growth retardation; SGA, small for gestational age.
They were included in the study at delivery ifbirthweight was below the third percentile on Leroy's chart (25) . Gestational age was determined from the last menstrual period, serial ultrasound examinations, and birth characteristics. The study was approved by the regional ethics committee.
Clinicalfindings. The mothers' clinical and obstetrical histories and the neonates' clinical characteristics were recorded respectively by the obstetricians and pediatricians, respectively.
Placental examination and sampling. 14 placentas (Pl-P14) from IUGR singletons were carefully examined. The mean gestational age was 36.3 wk. Placentas from six healthy women with uncomplicated singleton pregnancies, term delivery, and appropriate for gestational age (AGA) infants were used as controls.
Placentas were examined according to Benirschke and Kaufmann (26) , with macroscopic descriptions ofthe shapes and cords, parenchymal aspects, and the type of lesions, when present. Three samples for histologic examination were included in paraffin and stained with haematoxylin-eosin. Fresh tissue devoid of lesions was immediately treated for biochemical studies.
Placental biochemical study. (27) . Briefly, placental tissue was washed and minced in calcium-and magnesium-free ice-cold PBS, pH 7.4, and dissected into small pieces free of amnion, connective tissue, and blood clots. Microvillous plasma membranes were isolated from the washed tissue by gentle stirring with a magnetic stirrer in 50 ml of ice-cold saline buffer for 30 min at 40C, then filtered through four layers of cheese cloth. The filtrate was then centrifuged at 800 g for 10 min at 4VC. Microvillous fractions were pelleted by centrifugation of the supernatant at 50,000 g for 30 min at 4VC. After two washes in the same chilled medium, the pellet was resuspended in 150 ,l of 20 mM Tris HCl (pH 7.4), 50 mM NaCl, I mM CaCl2 and 2 mM MgCl2, frozen in liquid nitrogen, and kept at -80°C until use.
The purity of the samples was determined by colorimetric evaluation of membrane alkaline phosphatase activity (alkaline phosphatase kit; Biomerieux, Craponne, France). Protein was determined by a fluorometric assay with BSA as standard (28) .
EGF receptor autophosphorylation. Phosphorylation was determined according to Rao EGFR tyrosine kinase activity. In AGA microvillous membranes, EGF specifically induced phosphorylation of two proteins ( Fig. 1 A, lane A) : a 1 70-kD species identified as EGFR by immunoprecipitation with a specific anti-EGFR monoclonal antibody (Fig. 1 B) and a 35-kD species corresponding to lipocortine I, a substrate of EGFR tyrosine kinase (35, 36) .
SGA microvillous membranes displayed low ( Fig. 1 A, (Fig. 4) (Fig. 4 A, P9-P 14, and Table II , SGA, A) and significantly decreased (P < 0.002) in the other six cases (Fig. 4 B, P3-P8 , and Table II (Fig. 5, lane 1) . The labeling was abolished when the binding of [1251] EGF was performed with an excess of unlabeled EGF (lanes 2, 4, and 6). In all but one (P 14) ofthe SGA placentas, a 1 75-kD protein was observed. The labeling of this 175-kD EGFR was decreased in the six placentas with a small number ofmicrovillous EGFR (lane 3); it was increased in P2, and comparable to controls in the other five. In the SGA placenta P14, a single 145-kD membrane protein, was labeled (lane 5).
Immunoblotting ofEGFR. Western blots were performed with two polyclonal antibodies (RK2 and C-Term) prepared against denatured human EGFR protein (37) . Fig. 6 shows a representative autoradiograph of the 170-kD microvillous EGFR protein detected with RK2 and C-Term antibodies in AGA placentas (Fig. 6, lanes A and D) . A similar pattern was observed in the SGA placentas (except P14), with decreased immunodetection of EGFR in the six cases with a small number ofEGF binding sites (Fig. 6, lanes B and E) . EGFR was not detected in placenta P14 microvilli, with either C-Term or RK2 (Fig. 6, lanes C and F) .
The results of biochemical and immunochemical studies are summarized in Table III .
Discussion
Despite the prominent role of EGF in placental growth and function (38), few studies have been undertaken on placentas from IUGR pregnancies and no correlation has been sought with maternal and placental characteristics.
This study of 14 cases of IUGR shows an association between IUGR and altered placental EGFR activity, as demonstrated by a marked decrease in tyrosine kinase activity. 12 of the 14 SGA placentas displayed reduced or absent EGFR autophosphorylation. A specific loss of placental EGFR tyrosine kinase activity has been observed by Wang et al. ( 17) in pooled membrane fractions from smokers, but Scatchard analysis of EGF binding was not performed, and it was not stated whether smoking was associated with IUGR. All the placental membranes from the smokers with SGA neonates in our study showed impaired EGFR phosphorylation.
Various factors may result in impaired EGFR phosphorylation, such as a decreased number of EGF binding sites, unbalanced phosphatase activity, abnormal EGFR structure, and protein degradation. As placental membranes show phosphatase activity (39) (40) , assays were performed with AGA and SGA microvilli to determine whether a failure to detect EGFR kinase activity was caused by high tyrosine phosphatase activity; mixing SGA membranes with no EGFR phosphorylation and AGA membranes did not modify the pattern of EGF-dependent phosphorylated proteins in AGA membranes. Furthermore, the addition of a tyrosine phosphatase inhibitor, sodium vanadate, did not A reduced number ofEGF binding sites was observed in six membrane preparations from SGA pregnancies, and this may explain the decreased EGF-dependent tyrosine kinase activity. No such decrease was seen in the remaining six SGA placentas, although EGFR autophosphorylation was low or absent; such a dissociation between EGFR binding and receptor kinase activity has previously been described in human term placentas from smokers and from women exposed to polychlorinated biphenyls (43, 44) and have been associated with EGFR molecular weight alterations ( 17 ) . In our study of IUGR placentas, this discrepancy between normal EGF binding and absent EGFR tyrosine kinase activity was associated in five cases with a normal EGFR molecular weight and immunochemical recognition comparable to that in AGA placentas. A receptor mutation could explain the impaired signal transduction and loss of EGFR autophosphorylation in these five placentas (45, 46) . In one case (P 14) , the EGFR had normal binding capacity but no tyrosine kinase activity; its molecular weight ( 145 kD) was abnormal and its COOH-terminal intracellular domain was not labeled by a specific antibody, suggesting that it was a truncated form. Such an alteration of EGFR molecular weight has been described in placentas from smokers, but additional investigations of the receptor and protein sequencing would be required to sustain this hypothesis.
In our series of 14 placentas with IUGR, only one placenta (P2) from toxemic mother showed an increase in EGFR number (B.a = 5.30 pmol/mg protein). Comparable results were previously described (42) . However, it should be noticed that in this P2 placenta increase in EGFR number was not associated with a concomitant increase in tyrosine kinase activity, which remained in the normal range.
IUGR was not associated with maternal risk factors in about half the cases (n = 6), but abnormal placentas were observed in all cases but three, underlining the need to examine the placenta when evaluating IUGR. Maternal hypertension, a major cause of IUGR (24) , was prevalent in the subgroup with reduced placental EGF binding site numbers, and as expected, was associated with placental infarcts (47, 48 ). However, vascular lesions were also observed in the absence ofmaternal hypertension, mainly in placentas with normal EGFR numbers. Two placentas showed signs ofchronic villitis ofunknown etiology, which has been described in cases of IUGR, but its significance is unclear (49) . A long cord was the only abnormality in P13. No aetiology for IUGR was found three cases (P1, P12, and P14); -18% of cases of IUGR are considered "idiopathic" (50) . Nevertheless, EGFR tyrosine kinase activity was impaired in two of the three (P12 and P14) and associated in P14 with an abnormal EGFR molecular weight.
In conclusion, IUGR is associated with various alterations of placental EGFR. Early EGFR dysfunction could be linked to inadequate trophoblast differentiation and impaired migration ofextravillous cytotrophoblasts described in maternal toxemia (51, 52) and causing deficient perfusion of the intervillous space. Later in gestation, it may contribute to deficient villous syncytial metabolism. The impact ofEGF receptor alterations on placental function remains to be determined. 
